ABIVAX Société Anonyme (ABVX) Fair Value 2026

ABVX · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

LOW (30/100)

Quick Summary — As of 2026-08-27, ABIVAX Société Anonyme (ABVX) trades at $114.30. QOC: 5.5/10. Value Trap Risk: 30/100 (LOW). 0/13 models active.

Key Facts

Ticker
ABVX
Price
$114.30
Quality Score
5.5/10
Value Trap Risk
30/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give ABVX?

0 Intrinsic Value Models vs. Current Price ($114.30)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is ABIVAX Société Anonyme (ABVX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, ABIVAX Société Anonyme currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About ABVX?

0 of 13 models are currently active for ABVX. See which stocks rank higher →

How Does ABVX Rank in Biotechnology?

Among 620 Biotechnology stocks, ABVX ranks #216 by Quality of Company score. CirclFi's QOC score of 5.5/10 evaluates 32 fundamental signals. A score of 5.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, ABIVAX Société Anonyme operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating ABVX should weigh these sector-specific dynamics alongside our model-derived fair values.

Is ABVX a Value Trap?

CirclFi's Value Trap algorithm assigns ABVX a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for ABIVAX Société Anonyme. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, ABIVAX Société Anonyme's fundamental quality profile registers 5.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ABVX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy ABIVAX Société Anonyme Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

LENZLENZ Therapeutics, Inc.QOC 5.5GNLXGenelux CorporationQOC 5.5SPRYARS Pharmaceuticals, Inc.QOC 5.5SRRKScholar Rock Holding CorporationQOC 5.5ASBPAspire Biopharma Holdings, Inc.QOC 5.5IPHAInnate Pharma S.A.QOC 5.5SNGXSoligenix, Inc.QOC 4.8BIXTBioxytran, Inc.QOC 4.1QTTBQ32 Bio Inc.QOC 6.8EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: LENZ · GNLX · SPRY · SRRK · ASBP · IPHA · SNGX · BIXT · QTTB · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ABVX?

6 companies across all industries closest to ABVX’s Quality of Company score of 5.5/10.

USGOU.S. GoldMining Inc.QOC 5.5XWELXWELL, Inc.QOC 5.5BTOCArmlogi Holding Corp.QOC 5.5ELMEElme CommunitiesQOC 5.5MYNDMynd.ai, Inc.QOC 5.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: USGO · XWEL · BTOC · ELME · MYND · NVDA

Where Does ABVX Sit in CirclFi's Biotechnology Rankings?

ABVX is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About ABIVAX Société Anonyme’s Valuation?

What is ABIVAX Société Anonyme's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for ABIVAX Société Anonyme (ABVX). The Quality of Company score is 5.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ABVX overvalued or undervalued right now?

At $114.30, 0 of 0 active models suggest ABVX may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits ABIVAX Société Anonyme's business model in Biotechnology.

What does a Quality of Company score of 5.5 mean for ABVX?

ABIVAX Société Anonyme's QOC of 5.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ABVX?

CirclFi analyzes ABVX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is ABVX a value trap in 2026?

ABIVAX Société Anonyme's Value Trap score is 30/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns ABIVAX Société Anonyme (ABVX) a Quality of Company score of 5.5/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/ABVX/ · Methodology
Primary sources for this ABVX valuation
  • Financial statements: ABIVAX Société Anonyme 10-K and 10-Q filings on SEC EDGAR (CIK 0001956827) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for ABVX as of ; valuations recomputed .